Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73581190" target="_blank" >RIV/61989592:15110/17:73581190 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/17:A1801R4X RIV/65269705:_____/17:00067547 RIV/00843989:_____/17:E0106411
Result on the web
<a href="http://dx.doi.org/10.1080/10428194.2017.1298755" target="_blank" >http://dx.doi.org/10.1080/10428194.2017.1298755</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2017.1298755" target="_blank" >10.1080/10428194.2017.1298755</a>

Result language
angličtina
Original language name
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Original language description
The majority of multiple myeloma (MM) patients are 6+5 years of age or older at diagnosis (1). However, treatment of MM in the elderly remains challenging because older patients typically have a higher burden of chronic comorbidities, may experience increased drug-related toxicity, and are often ineligible for stem cell transplantation (2-7).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)